Effects of Investigational Pulmonary Fibrosis Drug


Trial Objective

Effects of Investigational Pulmonary Fibrosis DrugResearchers want to know if an investigational drug called BKS-986278 will help prevent or slow down the progression of pulmonary fibrosis, which is also known as lung fibrosis or interstitial lung disease. Researchers are studying the safety and efficacy of the drug and gathering information on the drug levels of this medication.


Active Clinical Trials Currently Recruiting

Who Can Participate

People who have been diagnosed with idiopathic pulmonary fibrosis (IPF) or progressive interstitial lung disease (PF-ILD) within the last seven years may be eligible for this study.

Age: IPF patients: 40+ PF-ILD patients: 21+    Gender: Any Gender

Estimated Time Commitment

34 weeks

If you complete the entire study, you will be asked to make up to 10 visits to the clinic and have one phone call follow-up.

Payment & Reimbursement  

Payment: Provided

Travel Reimbursement: Available

Trial Contact

For more information, contact:

Kris Eliopoulous

Kristina Eliopoulos

Request More Information

Trial Location

National Jewish Main Campus, Denver, CO

Trial Sponsors

Bristol-Myers Squibb

Principal Investigators


Request More Information

By completing this form, you agree to learn more about this study and see if you qualify.

 I would also like to receive periodic emails with health information, news and clinical research updates from National Jewish Health: